AbstractPurpose:. Melanoma brain metastases (MBM) are common in advanced melanoma and linked to poor prognosis. Preventing MBM can improve survival and reduce morbidity. Although dual-agent ...

The FDA gave accelerated approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo), a TROP-2 targeting antibody–drug conjugate (ADC), for patients with advanced or metastatic EGFR-mutated ...

Major Finding: An intraoperative sequencing workflow provides rapid turnaround of comprehensive molecular profiling of central nervous system (CNS) tumors. Concept: Methylation profile and DNA copy ...

Major Finding: Uptake of exogenous lipoproteins through glycosaminoglycans protects cancer cells from ferroptosis.Concept: Lipoproteins inhibit ferroptosis by delivering α-tocopherol, a form of ...

Adding pembrolizumab (Keytruda; Merck) to standard of care improved event-free survival for patients with head and neck squamous-cell carcinoma (HNSCC) in the phase III KEYNOTE-689 study, according to ...

AbstractImmune checkpoint blockers (ICB) targeting the PD-1/PD-L1 axis represent established therapies for many cancers. However, resistance occurs in most patients due to complex immune-suppressive ...

AbstractPurpose:. Hereditary colorectal cancer syndromes remain incompletely understood, with many cases lacking defined genetic causes. This study aimed to identify pathogenic mutations associated ...

In two observational studies that included more than 170,000 and 86,000 patients, respectively, with obesity and/or diabetes, researchers found that glucagon-like–peptide (GLP)-1 receptor agonists may ...

AbstractPurpose:. Combined inhibition of lymphocyte-activation gene 3 (LAG-3) and PD-1 improves outcomes in patients with melanoma. Increased LAG-3 expression in colorectal cancer correlates with ...

2 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for ...

Erdafitinib, a pan-FGFR tyrosine kinase inhibitor, was granted accelerated approval by the Food and Drug Administration (FDA) for patients with FGFR2/3-driven urothelial cancer based on the BLC2001 ...

Tol transgenic mice, tolerant to reporter proteins like luciferase and GFP, can be used to develop improved tumor models for studying metastasis and immunotherapy, avoiding immune rejection issues in ...